Evaluation of Peripheral Blood Protein Biomarkers for Colorectal Cancer Screening
NCT ID: NCT05520840
Last Updated: 2022-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
350 participants
INTERVENTIONAL
2022-09-30
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Blood Screening for Adult Colorectal Cancer
NCT05577143
Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III
NCT02556281
Observational Cross-reactivity Study for Colorectal Cancer Diagnosis
NCT06889844
Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice Highlands
NCT06119425
Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma
NCT01511653
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient referred for screening colonoscopy or for endoscopic resection
Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection
blood sampling for screening of biomarkers
Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sampling for screening of biomarkers
Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Other solid cancers or haematological malignancies that are progressive and/or undergoing treatment (apart from basal cell skin carcinoma)
* Contraindication to total colonoscopy
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OncoDiag
UNKNOWN
University Hospital, Caen
OTHER
University Hospital, Rouen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adrien Grancher, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Rouen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique du Cèdre
Bois-Guillaume, , France
Caen University Hospital
Caen, , France
Dijon University Hospital
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Aude DI FIORE
Role: primary
Karine BOUHIER, MD
Role: primary
Sylvain MANFREDI, Pr
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022/0149/HP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.